SygNola, LLC
9
6
6
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Open Wounds
Role: collaborator
Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Venous Leg Ulcers
Role: collaborator
Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Chronic Pressure Ulcers
Role: collaborator
Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers
Role: collaborator
Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds
Role: collaborator
Evaluating the Efficacy of NeoThelium FT in the Treatment of Venous Leg Ulcers
Role: collaborator
Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Diabetic Foot Ulcers
Role: collaborator
Evaluating the Efficacy of NeoThelium FT in the Treatment of Pressure Injuries
Role: collaborator
Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers
Role: collaborator
All 9 trials loaded